Pretreatment of Leukemic Cells With Low-Dose Decitabine Markedly Enhances the Cytotoxicity of Gemtuzumab Ozogamicin

Leukemia - United Kingdom
doi 10.1038/leu.2012.178
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Gemtuzumab Ozogamicin Makes a Comeback

Cancer Discovery
Oncology
2017English

Reinduction Chemotherapy With Gemtuzumab Ozogamicin and Intermediate/High-Dose Cytarabine: A Single-Center Experience

Open Journal of Blood Diseases
2014English

Antibody-Based Therapy of Acute Myeloid Leukemia With Gemtuzumab Ozogamicin

Frontiers in Bioscience - Landmark
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2013English

Low-Dose Methotrexate Enhances Cycling of Highly Anaplastic Cancer Cells

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2016English

High Dose Cytarabine Plus Gemtuzumab Ozogamicin for Patients With Relapsed or Refractory Acute Myeloid Leukemia: Cancer and Leukemia Group B Study 19902

Leukemia Research
Cancer ResearchOncologyHematology
2011English

The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia

Oncologist
Cancer ResearchMedicineOncology
2019English

Effective Treatment of Low-Dose Decitabine in Myelodysplastic Syndrome/Myeloproliferative Neoplasms

OncoTargets and Therapy
OncologyPharmacology
2017English

Resensitization of Cisplatin Resistance Ovarian Cancer Cells to Cisplatin Through Pretreatment With Low‐dose Fraction Radiation

Cancer Medicine
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2019English

Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Patients With Prior Gemtuzumab Ozogamicin: Literature Analysis of Survival After Defibrotide Treatment

Blood Cancer Journal
OncologyHematology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy